The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Abstract
Cancer incidence and deaths in the United States were projected for the most common cancer types for the years 2020 and 2030 based on changing demographics and the average annual percentage changes in incidence and death rates. Breast, prostate, and lung cancers will remain the top cancer diagnoses throughout this time, but thyroid cancer will replace colorectal cancer as the fourth leading cancer diagnosis by 2030, and melanoma and uterine cancer will become the fifth and sixth most common cancers, respectively. Lung cancer is projected to remain the top cancer killer throughout this time period. However, pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death by 2030, respectively. Advances in screening, prevention, and treatment can change cancer incidence and/or death rates, but it will require a concerted effort by the research and healthcare communities now to effect a substantial change for the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pancreatic ductal adenocarcinoma (PDAC) is on track to become the number 2 cancer killer in the United States within the next decade, unless there is a major improvement in outcomes.10”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [10]
Citations
Cites
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Research works printed but not linked: 18
- Siegel, 2014, Cancer Statistics, 2014, CA Cancer J Clin, 64, 9, 10.3322/caac.21208 · DOI · Paper page
- Smith, 2009, Future of cancer incidence in the United States: burdens upon an aging, changing nation, J Clin Oncol, 27, 2758, 10.1200/JCO.2008.20.8983 · DOI
- Jemal, 2013, Annual Report to the Nation on the Status of Cancer, 1975–2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels, J Natl Cancer Inst, 105, 175, 10.1093/jnci/djs491 · DOI
- Edwards, 2013 16, Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer, Cancer
- Matrisian, 2012, The alarming rise of pancreatic cancer deaths in the United States: why we need to stem the tide today
- Zauber, 2008, Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force, Ann Intern Med, 149, 659, 10.7326/0003-4819-149-9-200811040-00244 · DOI
- Mandel, 2000, The effect of fecal occult-blood screening on the incidence of colorectal cancer, N Engl J Med, 343, 1603, 10.1056/NEJM200011303432203 · DOI
- Edwards, 2010, Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates, Cancer, 116, 544, 10.1002/cncr.24760 · DOI · Paper page
- Davies, 2014 20, Current thyroid cancer trends in the United States, JAMA Otolaryngol Head Neck Surg, 10.1001/jamaoto.2014.1 · DOI
- Heller, 2007, Do all cancers need to be treated? the role of thyroglobulin in the management of thyroid cancer: The 2006 hayes martin lecture, Arch Otolaryngol Head Neck Surg, 133, 639, 10.1001/archotol.133.7.639 · DOI
- Welch, 2010, Overdiagnosis in Cancer, J Natl Cancer Inst, 102, 605, 10.1093/jnci/djq099 · DOI
- Bosch, 2004, Primary liver cancer: worldwide incidence and trends, Gastroenterology, 127, S5, 10.1053/j.gastro.2004.09.011 · DOI
- Bruix, 2011, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199 · DOI
- Spanknebel, 2001, Advances in the surgical management of pancreatic cancer, Cancer J, 7, 312
- Ma, 2013, Pancreatic cancer death rates by race among US men and women, 1970–2009, J Natl Cancer Inst, 105, 1694, 10.1093/jnci/djt292 · DOI
- Srivastava, 2008, Translational Research Working Group developmental pathway for biospecimen-based assessment modalities, Clin Cancer Res, 14, 5672, 10.1158/1078-0432.CCR-08-1267 · DOI
- Kaitin, 2010, Deconstructing the drug development process: the new face of innovation, Clin Pharmacol Ther, 87, 356, 10.1038/clpt.2009.293 · DOI
- Scientific framework for recalcitrant cancers 2013
Cited by
Sorted by citations
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Metadata
- Authors
- Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Venue
- Cancer Research
- Published
- 2014-05-29
- Volume
- 74
- Issue
- 11
- Pages
- 2913-2921
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1968812902
- Cited by
- 7,094
- References
- 1
- Citations by year
- 2026: 307 · 2025: 502 · 2024: 616 · 2023: 774 · 2022: 820 · 2021: 914 · 2020: 883 · 2019: 715 · 2018: 565 · 2017: 421 · 2016: 341 · 2015: 187 · 2014: 39
- FWCI
- 158.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Social Sciences › Demography › Insurance, Mortality, Demography, Risk Management
- Keywords
- cancer incidence projections, cancer mortality projections, thyroid cancer, liver cancer, pancreatic cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, melanoma, uterine cancer, cancer burden, United States
- MeSH terms
- Age Factors, Female, Forecasting, Humans, Lung Neoplasms, Male, Mortality, Pancreatic Neoplasms, Thyroid Neoplasms, United States, Models, Statistical, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
